Zealthy review
Zealthy (legal entity FitRX, LLC, recently renamed to Gronk Inc.) offers compounded semaglutide and tirzepatide via an asynchronous telehealth model.
Est. first month
From $286/mo (starting dose, plus a separate fee, compounded)
- Semaglutide
- From $286/mo (starting dose, plus a separate fee, compounded)
- Tirzepatide
- From $351/mo (starting dose, plus a separate fee, compounded)
- Coverage
- 34 states
- Brand-name
- Compounded only
The Value Score card
Zealthy scored on our six published factors. See the methodology.
Why it's a deal
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
Read the fine print
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database
The bottom line
Best for: Shoppers who want not currently recommended — listed for transparency and reader awareness only. Zealthy (legal entity FitRX, LLC, recently renamed to Gronk Inc.) offers compounded semaglutide and tirzepatide via an asynchronous telehealth model.
Ranked #382 of 395 programs we track — see our #1 deal, CoreAge Rx, for comparison.
Compare with other deals
The programs scoring closest to Zealthy, out of 394 others we track.
Shopping Zealthy against a specific rival? We put it head to head with our top-scoring pick on CoreAge Rx vs Zealthy, and every program that undercuts or outscores it is ranked on the Zealthy alternatives board.
- From $498/mo (all doses, medication billed separately, compounded)Rivas Medical Weight Loss— Rivas Medical Weight Loss is a physician-founded program (Paul Rivas MD LLC) combining 15 in-person clinics with telehealth across Maryland, Virginia, and Florida.55/100
- From $399/mo (compounded)TeleDocs360— TeleDocs360 is a cash-pay telehealth service offering compounded GLP-1 weight loss medications, including injectable semaglutide and tirzepatide, oral semaglutide, plus phentermine and NAD+ therapy.55/100
- From $349/mo (compounded)ClickSlim— Wyoming-registered telehealth selling compounded tirzepatide and NAD+ on introductory rates that step up after the first month, with no published state list.54/100
- Pricing not publishedWellorithm— Four compounded routes plus four branded pens — and not one price anywhere on the public site.51/100
- From $269/mo (compounded)Trimrose— Trimrose (Trimrose Inc.) is a cash-pay telehealth platform for compounded GLP-1 weight loss, offered as a weekly injection or a daily oral option.50/100
- From $449/mo (compounded)Valhalla Vitality— Valhalla Vitality is a telehealth wellness platform offering compounded semaglutide and tirzepatide for weight loss, alongside peptide and hormone therapies.50/100
More programs we track (24)
- #1 CoreAge Rx93
- #2 Ondra Health92
- #4 Vitara RX91
- #5 Gimme Care91
- #7 Alan Meds90
- #3 Trimi Health89
- #10 Precision Telemed89
- #11 bmiMD89
- #12 Care Clinics89
- #6 Oak88
- #16 Live Vital88
- #17 AmberHealth88
- #18 Fresh Day Meds88
- #8 Sesame Care87
- #9 Strut Health87
- #22 EverSlim87
- #23 NewSelf87
- #24 Vaylen87
- #25 Mint Med87
- #13 HealthRX86
- #14 RxSpan MD86
- #15 Sprout Health86
- #28 Bionomy Health86
- #29 BetterMe Rx86
364 more are reviewed too — see every GLP-1 program we track, ranked.
Pricing and coverage on this page were read from Zealthy's own website on ; the Value Score is our editorial judgment per the methodology. “% vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on Zealthy's site. Not medical advice; see our disclosure.